Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047686 | 1.00 | PTGS1 (0.80) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2094166 | 1.00 | PTGS1 (0.80) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL15442960 | 0.93 | KCNH2 (0.75) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1045088 | 0.93 | PTGS1 (0.81) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1044070 | 0.93 | PTGS1 (0.81) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1044069 | 0.93 | PTGS1 (0.81) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1045899 | 0.92 | PTGS1 (0.83) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1043389 | 0.92 | PTGS1 (0.83) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL1043388 | 0.92 | PTGS1 (0.83) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2093104 | 0.92 | PTGS1 (0.76) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| WO-2007043542-A9 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTGS1 1542/4885SLC6A2 3945/4885SLC6A4 3929/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTGS1 1542/4885SLC6A2 3945/4885SLC6A4 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.